| Erythropoietin and vascular endothelial growth factor as risk markers for severe hypoglycaemia in type 1 diabetes. | |
| | |
MedLine Citation:
|
PMID: 20566589 Owner: NLM Status: MEDLINE |
Abstract/OtherAbstract:
|
OBJECTIVE: Circulating erythropoietin (EPO) and vascular endothelial growth factor (VEGF) increase during hypoglycaemia and may represent protective hormonal counter-regulatory responses. We tested the hypothesis that low levels of EPO and VEGF are associated with a higher frequency of severe hypoglycaemia in a cohort of patients with type 1 diabetes. DESIGN: Prospective observational follow-up study. METHODS: Totally 219 patients with type 1 diabetes (41% females, age 46+/-13 years (mean+/-s.d.), duration of diabetes 21+/-12 years, and HbAlc 8.5+/-1.1%) were followed in a 1-year observational study. Plasma EPO and serum VEGF levels were measured at baseline with ELISA. Events of severe hypoglycaemia defined by third party assistance were recorded and validated in telephone interviews within 24 h. RESULTS: Totally 235 episodes of severe hypoglycaemia (1.1 episodes per patient-year) were reported by 82 patients (37%). At baseline, plasma EPO was 8.6 (3.1-34.3) U/l (median (range)), and serum VEGF was 52.2 (6.6-337) pg/ml. The levels of EPO and VEGF were not associated with frequency of severe and mild hypoglycaemia. The levels of EPO were not associated with age, sex, duration of diabetes, body mass index, HbAlc, C-peptide level or hypoglycaemia awareness status. The levels of VEGF were positively associated with age and female sex. CONCLUSIONS: Although several studies suggest that VEGF and EPO may affect brain function during hypoglycaemia, this study does not support random VEGF or EPO levels to determine future risk of severe hypoglycaemia in people with type 1 diabetes. |
| | |
Authors:
|
P L Kristensen; U Pedersen-Bjergaard; C Schalkwijk; N V Olsen; B Thorsteinsson |
Related Documents
:
|
12831339 - Insulin analogues and other developments in insulin therapy for diabetes. 16842489 - Treatment with insulin glargine does not suppress serum igf-1. 9083709 - Improved mealtime treatment of diabetes mellitus using an insulin analogue. multicenter... 11418149 - Activity of angiotensin-converting enzyme and risk of severe hypoglycaemia in type 1 di... 18406299 - Lispro insulin: benefits and limitations. 20001569 - Management of severe hypoglycaemia: cultural similarities, differences and resource con... 1437899 - Control of type ii diabetes. reaping the rewards of exercise and weight loss. 21035889 - Increased epicardial adipose tissue in type 1 diabetes is associated with central obesi... 20535309 - Status of association studies linking diabetes mellitus and periodontal disease in india. |
Publication Detail:
|
Type: Comparative Study; Journal Article; Research Support, Non-U.S. Gov't Date: 2010-06-21 |
Journal Detail:
|
Title: European journal of endocrinology / European Federation of Endocrine Societies Volume: 163 ISSN: 1479-683X ISO Abbreviation: Eur. J. Endocrinol. Publication Date: 2010 Sep |
Date Detail:
|
Created Date: 2010-08-18 Completed Date: 2010-09-09 Revised Date: - |
Medline Journal Info:
|
Nlm Unique ID: 9423848 Medline TA: Eur J Endocrinol Country: England |
Other Details:
|
Languages: eng Pagination: 391-8 Citation Subset: IM |
Affiliation:
|
Endocrinology Section, Department of Cardiology and Endocrinology, Hillerød Hospital, Dyrehavevej 29, DK-3400 Hillerød, Denmark. pelk@hih.regionh.dk |
Export Citation:
|
APA/MLA Format Download EndNote Download BibTex |
| MeSH Terms | |
Descriptor/Qualifier:
|
Adult Age Factors Biological Markers / blood Diabetes Mellitus, Type 1 / blood*, complications, diagnosis Erythropoietin / adverse effects, blood* Female Follow-Up Studies Humans Hypoglycemia / blood*, complications, diagnosis Male Middle Aged Prospective Studies Risk Factors Severity of Illness Index Sex Factors Vascular Endothelial Growth Factor A / adverse effects, blood* |
| Chemical | |
Reg. No./Substance:
|
0/Biological Markers; 0/VEGFA protein, human; 0/Vascular Endothelial Growth Factor A; 11096-26-7/Erythropoietin |
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine
Previous Document: Acute estrogen exposure does not affect basal VLDL-TG production or oxidation in post-menopausal wom...
Next Document: Association of the type 2 deiodinase Thr92Ala polymorphism with type 2 diabetes: case-control study ...